ArticleThoracic cancer2021

Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.

Esuteru Hirokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.